PMID- 36325978
OWN - NLM
STAT- MEDLINE
DCOM- 20230125
LR  - 20230202
IS  - 2055-5822 (Electronic)
IS  - 2055-5822 (Linking)
VI  - 10
IP  - 1
DP  - 2023 Feb
TI  - Cryoballoon ablation for atrial fibrillation in patients with heart failure with 
      mildly reduced and preserved ejection fraction.
PG  - 518-531
LID - 10.1002/ehf2.14212 [doi]
AB  - AIMS: Limited data are available on the outcomes of cryoballoon ablation 
      (CBA)-based pulmonary vein isolation (PVI) for atrial fibrillation (AF) in 
      patients with heart failure (HF) with preserved ejection fraction (HFpEF) and 
      mildly reduced ejection fraction (HFmrEF). The present study aimed to evaluate 
      the safety and effectiveness of CBA in such patients. METHODS AND RESULTS: 
      Consecutive patients with AF referred for CBA-based PVI from two highly 
      experienced electrophysiology centres were included in this retrospective study. 
      Of 651 patients undergoing CBA, 471 cases were divided into four groups: No HF 
      (n = 255), HFpEF (n = 101), HFmrEF (n = 78), and HF with reduced ejection 
      fraction (n = 37). Similar early recurrence of atrial arrhythmia was found among 
      groups (16.2% vs. 15.4% vs. 14.9% vs. 12.2%, P = 0.798), and no significant 
      difference of long-term sinus rhythm (SR) maintenance was identified among the 
      HFmrEF, HFpEF, and No HF groups (71.8% vs. 75.2% vs. 79.6%, P = 0.334). CBA is 
      safe for patients with HFmrEF and HFpEF with similar complications compared with 
      the No HF group (3.8% vs. 4.0% vs. 3.1%, P = 0.814). The reassessment of cardiac 
      function after CBA showed that patients with HF indicated beneficial outcomes. 
      Left atrial diameter (LAD) and left ventricular ejection fraction were 
      significantly improved in the HFmrEF group. There were 41.6% of patients in the 
      HFpEF group who were completely relieved from HF. LAD and New York Heart 
      Association (NYHA) were associated with recurrence in the HFpEF and HFmrEF 
      groups, and the maintenance of SR was an independent predictor of NYHA 
      improvement for all HF groups. CONCLUSIONS: Patients with HFmrEF and HFpEF could 
      benefit from CBA with high SR maintenance and significant HF improvement.
CI  - (c) 2022 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on 
      behalf of European Society of Cardiology.
FAU - Chen, Chaofeng
AU  - Chen C
AD  - Department of Cardiology, Shanghai Institute of Cardiovascular Diseases, 
      Zhongshan Hospital, Fudan University, Shanghai, China.
FAU - Cheng, Kuan
AU  - Cheng K
AD  - Department of Cardiology, Shanghai Institute of Cardiovascular Diseases, 
      Zhongshan Hospital, Fudan University, Shanghai, China.
FAU - Gao, Xiaofei
AU  - Gao X
AD  - Department of Cardiology, Affiliated Hangzhou First People's Hospital, Zhejiang 
      University School of Medicine, Hangzhou, Zhejiang, China.
FAU - Zou, Tian
AU  - Zou T
AD  - Department of Cardiology, Shanghai Institute of Cardiovascular Diseases, 
      Zhongshan Hospital, Fudan University, Shanghai, China.
FAU - Pang, Yang
AU  - Pang Y
AD  - Department of Cardiology, Shanghai Institute of Cardiovascular Diseases, 
      Zhongshan Hospital, Fudan University, Shanghai, China.
FAU - Ling, Yunlong
AU  - Ling Y
AD  - Department of Cardiology, Shanghai Institute of Cardiovascular Diseases, 
      Zhongshan Hospital, Fudan University, Shanghai, China.
FAU - Xu, Ye
AU  - Xu Y
AD  - Department of Cardiology, Shanghai Institute of Cardiovascular Diseases, 
      Zhongshan Hospital, Fudan University, Shanghai, China.
FAU - Xu, Yizhou
AU  - Xu Y
AD  - Department of Cardiology, Affiliated Hangzhou First People's Hospital, Zhejiang 
      University School of Medicine, Hangzhou, Zhejiang, China.
FAU - Chen, Qingxing
AU  - Chen Q
AD  - Department of Cardiology, Shanghai Institute of Cardiovascular Diseases, 
      Zhongshan Hospital, Fudan University, Shanghai, China.
FAU - Zhu, Wenqing
AU  - Zhu W
AD  - Department of Cardiology, Shanghai Institute of Cardiovascular Diseases, 
      Zhongshan Hospital, Fudan University, Shanghai, China.
FAU - Ge, Junbo
AU  - Ge J
AD  - Department of Cardiology, Shanghai Institute of Cardiovascular Diseases, 
      Zhongshan Hospital, Fudan University, Shanghai, China.
LA  - eng
GR  - 21S31906903/Science and Technology Commission of Shanghai Municipality/
PT  - Journal Article
DEP - 20221103
PL  - England
TA  - ESC Heart Fail
JT  - ESC heart failure
JID - 101669191
SB  - IM
MH  - Humans
MH  - *Atrial Fibrillation/complications
MH  - Stroke Volume/physiology
MH  - Retrospective Studies
MH  - Ventricular Function, Left/physiology
MH  - *Heart Failure
MH  - Prognosis
MH  - *Ventricular Dysfunction, Left
PMC - PMC9871672
OTO - NOTNLM
OT  - Atrial fibrillation
OT  - Cryoballoon ablation
OT  - Heart failure with mildly reduced ejection fraction
OT  - Heart failure with preserved ejection fraction
OT  - Safety and effectiveness
COIS- The authors declare no potential conflict of interest.
EDAT- 2022/11/04 06:00
MHDA- 2023/01/26 06:00
PMCR- 2022/11/03
CRDT- 2022/11/03 05:43
PHST- 2022/09/21 00:00 [revised]
PHST- 2022/03/11 00:00 [received]
PHST- 2022/10/14 00:00 [accepted]
PHST- 2022/11/04 06:00 [pubmed]
PHST- 2023/01/26 06:00 [medline]
PHST- 2022/11/03 05:43 [entrez]
PHST- 2022/11/03 00:00 [pmc-release]
AID - EHF214212 [pii]
AID - 10.1002/ehf2.14212 [doi]
PST - ppublish
SO  - ESC Heart Fail. 2023 Feb;10(1):518-531. doi: 10.1002/ehf2.14212. Epub 2022 Nov 3.